Patients' characteristics:
|
Age:
|
Mean: 67
|
Range: 32-98
|
|
Gender:
|
105 Males (80%)
|
26 Females (20%)
|
|
High-risk:
|
63%
|
|
|
Intermediate risk:
|
37%
|
|
| The High Risk patients (83)
had an average of 3.4 occurrences prior to being
referred to Synergo. |
| The Interediate Risk patients (48)
had an average of 3.2 occurrences prior to being reffered to Synergo.
The average disease-free interval for this group was 362 days.
|
Number of patients with 3 or more recurrences in previous 24 months:
26 (19.8%)
(high recurrence)
|
Number of patients who had previously undergone BCG therapy :
37 (28%)
|
Number of patients who had previously
undergone instillations : 73 (56%)
|
Results
| 1. |
The results for the 131 prophylactic patients are:
All patients: 28 recurred (20.0%)
High Risk patients: 21 recurred (25%) with a 2-year K-M estimated recurrence rate of 40%
Intermediate Risk patients: 7 recurred (14.5%) with 2-year K-M estimated
recurrence rate of 31%.
|
| 2. |
Progression to T>T1 was observed in 2 patients only after a mean follow-up
of 13 months (range 2-66months)
|
| 3. |
Side effects:
Mild pain during session, dysuria, hematuria and frequency during the first day after treatment.
All patients resumed normal daily activity after each treatment.
|
|
Homepage |
